Emerging pharmacologic treatment options for fragile X syndrome
Tori L Schaefer, Matthew H Davenport, Craig A Erickson Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA Abstract: Fragile X syndrome (FXS) is the most common single gene cause of intellectual disability and autism spectrum disor...
Main Authors: | Schaefer TL, Davenport MH, Erickson CA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-04-01
|
Series: | The Application of Clinical Genetics |
Online Access: | http://www.dovepress.com/emerging-pharmacologic-treatment-options-for-fragile-x-syndrome-peer-reviewed-article-TACG |
Similar Items
-
Systematic review of pharmacological treatments in fragile X syndrome
by: Tejada Maria-Isabel, et al.
Published: (2009-10-01) -
Neurodevelopment and early pharmacological interventions in Fragile X Syndrome
by: Luis A. Milla, et al.
Published: (2023-08-01) -
Developmental studies in fragile X syndrome
by: Khaleel A. Razak, et al.
Published: (2020-05-01) -
Emerging pharmacological treatment options for MAFLD
by: Ángela Rojas, et al.
Published: (2022-12-01) -
Pharmacological options for pain control in patients with vertebral fragility fractures
by: Nuttan Kantilal Tanna, et al.
Published: (2022-09-01)